Skip to main content
. 2012 Jul 9;10:18. doi: 10.1186/1478-811X-10-18

Figure 6.

Figure 6

The PI3K/Akt pathway is required for survival of MCF-7 but not MDA-MB-231 cells. MCF-7 and MDA-MB-231 cells were treated with various concentrations of LY294002 for 48 h. (A) Immunoblot of p-Akt in MCF-7 and MDA-MB-231 cells treated with LY294002. (B) Effects of LY294002 treatment on viability as determined by trypan blue exclusion assays (n = 3). (C) Immunoblot of PARP cleavage in MCF-7 and MDA-MB-231 cells treated with LY294002.